This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Top Stock Charts for This Week
by Tracey Ryniec
Tracey Ryniec talks about a new strategy for Q1 earnings season, including impacts of the tariffs, on ABT, TSM, AXP, MAN, and DHI.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
International Growth Drives GMED Stock Amid Fierce Competition
by Zacks Equity Research
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
by Zacks Equity Research
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
Bruker Stock May Benefit Following Its Investment in Ridom GmbH
by Zacks Equity Research
BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
by Zacks Equity Research
BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.
Seeking Clues to Abbott (ABT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Abbott (ABT) Stock Moves -2%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $124.50 in the latest trading session, marking a -2% move from the prior day.
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
by Zacks Equity Research
ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Should You Continue to Hold NVST Stock in Your Portfolio?
by Zacks Equity Research
Investors are optimistic about Envista, thanks to its strong momentum in the Specialty Products and Technologies segment.
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day.
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On
by Urmimala Biswas
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is it the Right Time to Retain Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts
by Zacks Equity Research
ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.
ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps
by Zacks Equity Research
ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.
Bruker Announces Groundbreaking 1.3 GHz NMR System, Stock Up
by Zacks Equity Research
BRKR's new 1.3 GHz high-resolution NMR system comes with a stable, standard-bore 54 mm superconducting magnet.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
The Zacks Analyst Blog Highlights Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare
by Zacks Equity Research
Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare are included in this Analyst Blog.
Hologic Brings in New Leadership: A Signal to Stay Put With the Stock?
by Moumi Mondal
HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag.
5 Defensive Stocks to Buy for a Safe Portfolio Amid Tariff-Led Mayhem
by Nalak Das
Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.